1-7 of 7
Hans Michael Kvasnicka, MD, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2948.
https://doi.org/10.1182/blood-2019-124343
Published: 2019
Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2016) 128 (22): 1949.
https://doi.org/10.1182/blood.V128.22.1949.1949
Published: 2016
Journal Articles

Ruxolitinib Therapy Effectively Modulates CD34 + Hematopoietic Progenitors and Bone Marrow Angiogenesis in Patients with Myelofibrosis

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 4578.
https://doi.org/10.1182/blood.V124.21.4578.4578
Published: 2014
Journal Articles

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Jorge E. Cortes, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3182.
https://doi.org/10.1182/blood.V124.21.3182.3182
Published: 2014
Journal Articles

Changes in Activated Bone Marrow Macrophages and Mast Cells in Patients with Myelofibrosis Following Ruxolitinib Therapy

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MDPhD, Carlos E. Bueso-Ramos, MD PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop Kantarjian, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3184.
https://doi.org/10.1182/blood.V124.21.3184.3184
Published: 2014
Journal Articles

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Hans Michael Kvasnicka, MD, PhD, Jürgen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, William Sun, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4055.
https://doi.org/10.1182/blood.V122.21.4055.4055
Published: 2013
Journal Articles

Effects Of Ruxolitinib Therapy On Megakaryocyte Morphology and Inflammatory Bone Marrow Reaction In Patients With Myelofibrosis

Hans Michael Kvasnicka, MD, PhD, Juergen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Shilpa Kamalanabhaiah, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4056.
https://doi.org/10.1182/blood.V122.21.4056.4056
Published: 2013